PTPRC and Bloom syndrome: Similarly, Mansouri et al. [23] reported that the administration of BMSC-EXOs reduced the number of classic proinflammatory monocytes (CD45+CD11b+MHCII−CD64lo/intCCR2+Ly6Cchi) while simultaneously increasing the levels of nonclassic monocytes (CD45+CD11b+MHCII−CD64lo/intCCR2−Ly6Clo) and AMs (CD45+ CD11b−CD11c+CD64+) to mitigate BLM-induced PF.